CABOZANTINIB and BLISTER

Overview

BLISTER is the #15 most commonly reported adverse reaction for CABOZANTINIB, manufactured by Exelixis, Inc.. There are 2,004 FDA adverse event reports linking CABOZANTINIB to BLISTER. This represents approximately 1.8% of all 112,838 adverse event reports for this drug.

Patients taking CABOZANTINIB who experience blister should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

BLISTER is a less commonly reported adverse event for CABOZANTINIB, but still significant enough to appear in the safety profile.

Other Side Effects of CABOZANTINIB

In addition to blister, the following adverse reactions have been reported for CABOZANTINIB:

• DIARRHOEA — 8,862 reports
• FATIGUE — 7,232 reports
• OFF LABEL USE — 5,626 reports
• NAUSEA — 4,661 reports
• DECREASED APPETITE — 4,365 reports
• MALIGNANT NEOPLASM PROGRESSION — 3,031 reports
• BLOOD PRESSURE INCREASED — 3,018 reports
• PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME — 2,878 reports
• WEIGHT DECREASED — 2,846 reports
• DEATH — 2,741 reports

Other Drugs Associated with BLISTER

The following drugs have also been linked to blister in FDA adverse event reports:

Does CABOZANTINIB cause BLISTER?

BLISTER has been reported as an adverse event in 2,004 FDA reports for CABOZANTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is BLISTER with CABOZANTINIB?

BLISTER accounts for approximately 1.8% of all adverse event reports for CABOZANTINIB, making it a notable side effect.

What should I do if I experience BLISTER while taking CABOZANTINIB?

If you experience blister while taking CABOZANTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages